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Abstract 
Background 
Although the link between cannabis use and development of psychosis is well 
established, less is known about the impact of continued versus discontinued cannabis 
use after the onset of the illness. No meta-analysis has as yet summarized the 
evidence focusing on the relationship between continued and discontinued cannabis 
use following onset of psychosis and its relapse. 
Methods 
Studies were identified through a systematic literature search. Relapse outcomes were 
compared between those who continued (CC) or discontinued (DC) cannabis use or 
were non-users (NC). Cohen’s d was estimated and entered into Random Effects 
Models (REM) to compare (1) CC-NC, (2) CC-DC and (3) DC-NC. Meta-regression 
and sensitivity analysis were employed to address the issue of heterogeneity.  
Findings 
Twenty-four studies (N=16565) were included. Independent of the stage of illness, 
continued cannabis users had significantly (p<0·05) worse relapse outcome than both 
non-users (dCC-NC=0·36) and discontinued users (dCC-DC=0·28), as well as longer 
hospitalizations (dCC-NC=0·32). In contrast, cannabis discontinuation was not 
associated with relapse (dDC-NC=0·02, p=0·82). Meta-regression indicated greater 
effects of continued compared to discontinued cannabis use (p<0·05) on relapse, 
positive symptoms and level of functioning but not negative symptoms. 
Interpretation 
Continued cannabis use after onset of psychosis predicts adverse outcome, including 
higher relapse rates, longer hospitalizations and more severe positive symptoms - 
adverse effects that are absent in those who discontinue use of cannabis. These 
findings point to reductions in cannabis use as a crucial interventional target to 
improve outcome in patients with psychosis. 
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Introduction 
Cannabis is the most commonly used illicit drug in patients with an existing psychotic 
disorder 1. In some studies about one out of every four patients with psychosis meet 
the criteria for cannabis dependence 2,3 with rates of use especially high in young 
people presenting with their first psychotic episode 2. These rates are much higher 
than those of the general population 4 or those with other psychiatric diagnoses 5. 
While the association between cannabis use and onset of psychotic disorders is well-
established 6,7, suggesting that cannabis use is a component cause of the disorder 8, its 
effect on the course of psychosis following onset is less clear. This lack of clarity 
seems mainly related to limitations of study design such as cross-sectional approach, 
underpowered samples and lack of consideration of potential confounders (reviewed 
here 9). However, more recent studies implicate cannabis use as a potential risk factor 
for relapse of psychosis as indexed by readmission to hospital 10-12, with some 
evidence supporting a dose-response relationship 13. Other studies reported worsening 
of positive psychotic symptoms 14,15 or shorter time to symptom re-emergence 16 in 
cannabis-using patients with psychosis. These findings are in line with experimental 
pharmacological challenge studies reporting that delta-9-tetrahydrocannabinol (THC), 
the main psychoactive constituent in cannabis, can induce transient psychotic 
experiences in healthy individuals and worsen existing symptoms in patients with pre-
existing psychosis 17-20.  
If cannabis use were really associated with worse outcome in those with established 
psychosis, then one would expect that those who continue using cannabis would have 
far worse outcome compared to those who stop. However, while some evidence 
suggests that discontinuation of cannabis use may lead to a reduction in readmission 
rates 21,22 and improvement in symptomatic and functional outcome of psychosis 15,22-
26, others suggest that this may not necessarily be the case 1,10, 27,28. Although, about 
30-50% of cannabis users stop using it after the onset of their psychotic illness 15,21-
23,29 suggesting that this may be a clinically relevant issue worth exploring, there is 
lack of clarity in terms of existing evidence as outlined earlier. Furthermore, 
conclusions from the individual studies need to be treated with caution in light of the 
relatively modest sample sizes. Meta-analytic techniques offer a method of 
overcoming the sample size issue by statistically integrating the results from a number 
of separate studies thereby improving the power to detect significant effects30. 
Considering the conflicting evidence from individual studies investigating the 
relationship between continued cannabis use and relapse and from studies looking at 
discontinued use and outcome, we have attempted to quantitatively summarize the 
current evidence. We aimed to (a) establish whether ongoing cannabis use is 
associated with poor outcome in established psychosis and (b) establish the magnitude 
of this effect by pooling together the results of all available studies using a meta-
analytic approach. In particular, we focused on outcome defined as ‘relapse of 
psychosis’, operationalized as either readmission to hospital or based on investigator-
determined psychotic relapse. Since cannabis use is potentially amenable to treatment 
and given that a substantial proportion of patients with psychosis continue using the 
drug following onset of their illness, there is a particular need to estimate the effect of 
ongoing cannabis use on a robust measure of outcome which is indicative of relapse, 
such as hospitalization. This is a reliably estimated measure, with significant 
implications for the cost of healthcare 31. Although previous meta-analyses have 
investigated the association between continued and discontinued cannabis use and 
outcome in psychosis, these have mainly focused on symptomatic outcome measures 
such as positive and negative symptoms or depression scores, while outcome indexed 
by hospitalization was only considered in the context of the effects of substance use in 
general.32-34. We therefore set out to investigate whether (i) continued use of cannabis 
following the onset of psychosis is associated with worse relapse outcome relative to 
non-users, (ii) discontinued use of cannabis subsequent to the onset of psychosis is 
associated with a worse relapse outcome comparable to non-users and (iii) 
discontinued use of cannabis is associated with a better relapse outcome compared to 
continued use. Furthermore, we investigated whether the effect of cannabis use on 
outcome was consistent across different outcome measures by also examining effect 
on measures such as length of hospitalization, symptom severity and level of 
functioning.  
2. Methods 
Study selection 
A systematic search strategy was used to identify all relevant studies, following the 
methods recommended by the Cochrane Handbook 35 and in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines 36. Firstly, the MEDLINE database was searched for English language 
studies using a combination of search terms describing the cannabis terms 
(marijuana/marihuana, cannabis, illicit, substance), the outcome of interest (outcome, 
hospital*, relapse, readmission) and the study population (psycho*, bipolar, 
schizophrenia), with the final search conducted on the 21st of April 2015. Following 
this, bibliographies of the identified publications and previous published meta-
analyses were hand-searched in order to identify additional studies that met the 
inclusion criteria but might have been missed by the database search. Studies were 
selected if they included a sample of patients with a pre-existing psychotic disorder 
(schizophrenia, schizoaffective, bipolar if outcome was reported as number of 
psychotic episodes [e.g. Ringen et al. (2010)37]), with a follow-up duration of at least 
6 months. The primary predictor variables were defined as (1) continued cannabis use 
(yes/no) after onset of illness and (2) discontinued cannabis use after onset (yes/no). 
Only a subset of the total pool of studies that examined the effect of continued 
cannabis use on outcome also examined the effect of discontinuation of the drug. We 
excluded studies if ‘continued cannabis use’ (CC)/ ‘discontinued cannabis use’ (DC) 
could not be established, e.g. studies that assessed cannabis use only around the onset 
of illness 38-41 and studies that only reported lifetime cannabis use 42-45. The primary 
outcome was defined as ‘relapse of psychosis’, which was indexed as either (1) 
readmission to hospital, (2) investigator-determined relapse [operationalized in 
manuscript as ‘psychotic episode’ or exacerbation of psychotic symptoms 16,22,46] or 
(3) investigator-determined relapse but without any reported criteria for 
operationalization 47 (cf. Table 1.). If the identified studies reported symptom scores 
(positive, negative), length of hospitalization (time spent in hospital) or level of 
functioning (as measured with the Global Assessment of Functioning Scale 48) 
alongside the relapse information, this data was also extracted and used in separate 
outcome analyses. An initial data extraction protocol was drafted in 2013 and data 
extraction was piloted from studies identified through a systematic search by at least 
two independent researchers to finalize the selection criteria and variables of interest. 
Data was extracted by two independent researchers (TS and one other researcher). 
Disagreements were resolved through discussion between the researchers extracting 
data and a senior researcher (SB). 
Quality assessment 
We used a modified seven-point ‘strength of reporting scale’ which has been 
employed in previous meta-analyses conducted in a related area of research 32,34. This 
scale is based on items describing methodological aspects in the ‘Strengthening the 
Reporting of Observational Studies in Epidemiology’ (STROBE) 49 checklist. Studies 
with a score of >5 were classified as higher quality studies (cf. sTable 1., 
supplementary material). 
Statistical analysis 
Analyses were conducted with R and its package metaphor 50, using random effects 
models (REM) 51 that assume that effect sizes vary from study to study 52. Effect sizes 
were estimated using Cohen’s d, where d-values of 0·2 represent small effects, d-
values between 0·4 and 0·6 represent moderate effect and d-values of 0.8 or higher 
indicate large effects 53. d per study was calculated for the comparisons (1) continued 
cannabis use vs. non-user (CC-NC), (2) continued use vs. discontinued use (CC-DC)  
and (3) discontinued use vs. non-user (DC-NC). The R-package Compute.es 54 was 
used, which allows data from included studies to be entered in the form of means and 
standard deviations 37, p-values for mean comparisons or chi square statistics to reach 
an approximated d. In addition, the package allowed the estimation of d for those 
studies that reported odds ratios 11,12. In those cases where the SD was not reported 
55,56, the SD was extrapolated from other studies with similar outcome and sample 
characteristics. We carried out meta-regression analysis for categorical variables to 
compare the estimated d’s between the groups CC-NC and DC-NC for outcome 
(relapse, length of hospitalization, positive symptoms, negative symptoms, 
functioning). In addition, meta-regression was used to test whether the effect of 
cannabis was confounded by the stage of illness of participants in the studies included 
[i.e. early psychosis vs. chronic psychosis, with chronic psychosis referring to those 
subjects with an illness length of more than 5 years as classified in previous studies 
57]. Finally, meta-regression for continuous moderators was used to test the effect of 
gender (percentage of sample being male) and age at the time of study assessment. 
The possibility of publication bias was examined using funnel plots, followed by the 
Egger’s linear regression test 58 to test funnel plot asymmetry for significance.  
Homogeneity of the distribution of weighted effect sizes was tested with the Q test, 
and degree of heterogeneity was quantified using the I2 test, which describes the 
percentage of observed heterogeneity that would not be expected by chance 59. I2 
values between 0 and 25% suggest small heterogeneity, while I2 values in the range 
25% and 50% suggest moderate heterogeneity, and those >50% indicate large 
heterogeneity.  
Sensitivity analysis 
Given the heterogeneity in the definition of relapse employed by the studies, we 
carried out sensitivity analyses restricting the studies to only those investigating 
hospital admissions, which has been reported to be a valid measure of relapse in 
psychosis 60.  Similarly, in the light of variation in follow-up duration between 
cannabis users and non-users in the studies (cf. Table 1.), we carried out subset 
analyses by including only those studies in which cannabis users were matched to the 
non-users with respect to their follow up duration (indicated as “Matched = YES” if 
the difference was not more than 1 year between the groups, cf. Table 1.). 
2.1 Role of the funding source 
The funder of the study had no role in study design or collection, analysis and 
interpretation of data, or writing of the report. All authors had access to the data and 
have approved the final version of the paper. 
3. Results 
Study selection 
Out of 1903 identified studies, 24 met inclusion criteria, comprising 5849 individuals 
with continued cannabis use following psychosis onset and 10308 who were classified 
as non-users (cf. Flow Chart, Figure 1.). Screening of studies published in languages 
other than English (n=126) did not yield any additional studies meeting our inclusion 
criteria (cf. sFigure 1., supplementary material). A subset (n=6) of the included 
studies included an additional group of patients that were classified as discontinued 
cannabis users (408 discontinued users, 268 continued users and 496 non-users). 
 
Figure 1 (Flow chart) about here 
Table 1. Effects of cannabis continuation after onset and discontinuation after onset on relapse outcome 
Continued Cannabis use 
Study / Country Definition continued 
cannabis use 
Definition cannabis 
non-user  
Relapse outcome Length of Illness 
(LI) in years at 
FU; Illness stage 
(Early vs Chronic)  
FU duration 
(years) 
[Matched 
YES/No] 
N d 
[95% 
CI] 
OR 
[95% 
CI] 
Baeza, Graell (2009)26 / 
Spain 
Use in 1 month prior FU 
assessment (n=15) 
No cannabis history 
(n=69) 
Number of re-
hospitalizations in 6 
months FU 
LI: 1 
Early stage 
 
0·5 (CAN +)  
0·5 (CAN -) 
[YES] 
84 0         
[-0.57; 
0.57] 
N/A 
Barrowclough, Emsley 
(2013)1 / UK 
Use (any) in previous 90 
days (n=160) 
No use in previous 90 days 
(n=167) 
Hospitalization (y/n) in 
previous year 
LI: 12 
Chronic 
1 (CAN +)  
1 (CAN -) 
[YES] 
327 0·33 
[0.11; 
0.55] 
1.82 
[1.22; 
2.71] 
Bersani et al. (2002)61 / 
Italy 
Current user (NS) (n=54) No cannabis history 
(n=71) 
Number of previous 
hospitalizations 
LI: 10 
Chronic 
8  (CAN +)  
13 (CAN -) 
[NO] 
125 -0·07  
[-0.43; 
0.29] 
N/A 
Caspari (1999)62 / 
Germany 
Cannabis abuser (n=27) c Non-abuser (n=26) Number of 
rehospitalizations 
following index 
hospitalization 
LI: 7 
Chronic 
5 (CAN +)  
6 (CAN -) 
[YES] 
53 1·04 
[0.56; 
1.52] 
N/A 
Faridi, Joober (2012)47 / 
Spain 
Presence of CUD at FU 
(n=28) 
Absence of CUD at FU 
(n=20) 
Relapse (y/n) in 1 year 
FU (NS) 
LI: 1 
Early stage 
1 (CAN +)  
1 (CAN -) 
[YES] 
48 0·04   
[-0.55; 
0.63] 
1.08 
[0.37; 
3.13] 
González-Pinto, Alberich 
(2009)21 / Spain 
Continued use 
throughout 7 years FU 
(n=25) 
No cannabis history 
(n=40) 
Number of 
hospitalizations in 8 
years FU 
LI: 8 
Chronic 
8 (CAN +)  
8 (CAN -) 
[YES] 
65 0·58 
[0.06; 
1.10] 
N/A 
Isaac et al. (2005)63 / UK +ve UDS (n=69) at 
admission 
-ve UDS (n=46) at 
admission 
Number of previous 
hospitalizations 
N/A NOT 
REPORTED 
115 0·62 
[0.24; 
1.01] 
N/A 
Jockers-Scherubl et al. 
(2007)64 / Germany 
Presence of CUD (n=19) No Use < 5 times/ lifetime 
(n=20) 
Number of previous 
hospitalizations 
LI:7 
Chronic 
6 (CAN +) 
9 (CAN -) 
[NO] 
39 -0·40   
[-1.05; 
0.26] 
N/A 
Koenders, Machielsen 
(2014)46 / Netherlands 
Presence of CUD (n=80) 
 
Use <  5 times/ lifetime 
(n=33) 
 
Number of previous 
psychotic episodes 
(NS) 
LI: 1 
Early stage 
1 (CAN +)  
1 (CAN -)  
[YES] 
113 0·12    
[-0.43; 
0.39] 
N/A 
Linszen et al. (1994)65 / 
US 
Presence of CUD (n=24) 
in 1 year FU 
Absence of CUD (n=69) in 
1 year FU 
Relapse (y/n) 
(exacerbation of 
psychotic symptomsb) 
in 1 year FU 
LI: 3 
Early stage 
1 (CAN +)  
1 (CAN -) 
[YES] 
93 0·45 
[0.07; 
0.88] 
2.27 
[1.05; 
4.89] 
Maremmani et al. 
(2004)66 / Italy 
Lifetime CUD and +ve 
UDS (n=43) 
No cannabis history 
(n=45) 
Number of previous 
hospitalizations 
LI: 10 
Chronic 
7 (CAN +)  
12 (CAN -) 
[NO] 
88 -0·08   
[-0.51; 
0.34} 
N/A 
Martinez-Arevalo et al. 
(1994)67 / Spain 
Use during 1 year FU 
(NS) (n=14) 
No cannabis history 
(n=24) 
Hospitalization (y/n) in 
1 year FU 
LI: 2 
Early stage 
1 (CAN +)  
1 (CAN -)  
38 0·46   
[-0.23; 
2.29 
[0.66; 
1.14] 7.91] 
Negrete, Knapp (1986)55 
/ Canada 
Use in 6 months prior to 
FU assessment and/or 
+ve UDS (n=25) 
No cannabis history 
(n=61) 
Number of previous 
hospitalizations 
LI: 10 
Chronic 
6 (CAN +)  
13 (CAN -) 
[NO] 
86 0·8 
[0.31; 
1.29] 
N/A 
Peralta and Cuesta 
(1992)68 / Spain 
Use > 1 time/week in 
year prior to assessment 
(n=23) 
Use < 1 time/week in year 
prior assessment (n=72) 
Number of previous 
hospitalizations 
LI: 5 
Early stage 
5 (CAN +)  
6 (CAN -) 
[YES] 
95 -0·14  
[-0.62; 
0.34] 
N/A 
Rehman and Farooq 
(2007)69 / Pakistan 
Use in 1 year prior 
assessment (n=50) 
No use in year prior 
assessment (n=50) 
Number of previous 
hospitalizations 
LI: 5 
Early stage 
4 (CAN +)  
5 (CAN -) 
[YES] 
100 0·40  [-
0.002; 
0.80] 
N/A 
Rentzsch et al. (2011)70 / 
Germany 
Current user (> 5 
days/week for > 1 year) 
(n=27) 
Use < 5 times/ lifetime 
(n=26) 
Number of previous 
hospitalizations 
LI: 6 
Chronic 
5 (CAN +) 
7 (CAN -) 
[NO] 
53 0.25    
[-0.31, 
0.80] 
N/A 
Ringen, Vaskinn 
(2010)37 / Norway 
Use in 6 months prior FU 
assessment (NS) (n=41) 
No use in 6 months prior 
FU assessment (n=232) 
Number of previous 
hospitalizations 
LI: 8 
Chronic 
7 (CAN +)  
9 (CAN -) 
[NO] 
273 0·20   
[-0.13; 
0.54] 
N/A 
Salyers and Mueser 
(2001)71 / US 
> 1 time during 6 months 
prior FU assessment (n= 
363) 
Never used in 6 months 
prior FU (n=41) 
Number of 
hospitalizations in 2 
years prior FU 
assessment 
LI: 8 
Chronic 
2 (CAN +)  
2 (CAN -) 
[YES] 
404 0·37 
[0.04; 
0.69] 
 
N/A 
San, Bernardo (2013)11 / 
Spain 
Use in 4 years prior FU 
assessment (n=553) 
No use in 4 years prior FU 
assessment (n=1093) 
Hospitalization (y/n) in 
1 year FU 
LI: >10 years for 
57% of the sample 
Chronic 
1 (CAN +)  
1 (CAN -) 
[YES] 
1646 0·25 
[0.13, 
0.36] 
1.56 
[1.27; 
1.92] 
Sara et al. (2014)72 / 
Australia 
Presence of CUD in 5 
years FU (n=3946) 
Absence of CUD in 5 
years FU (n=7672) 
Number of 
rehospitalizations in 5 
years FU 
LI: > 7  
Chronic 
5 (CAN +)  
5 (CAN -) 
[YES] 
11618 0·92 
[0.89; 
0.96] 
 
Sorbara, Liraud (2003)12 
/ France 
Presence of CUD in 2 
years following onset 
(n=9) 
Absence of CUD in 2 
years following onset 
(n=49) 
Hospitalization (y/n) in 
2 years following onset 
LI: 2 
Early stage 
2 (CAN +)  
2 (CAN -) 
[YES] 
58 0·62 
[0.01; 
1.24] ] 
3.1 
[1.01; 
9.4] 
van Dijk et al. (2012)73 / 
Netherlands 
> 4 times during 1 year 
FU or use 1 month prior 
FU assessment (n=68) 
< 4 times during 1 year FU 
or no use 1 month prior FU 
assessment (n=77) 
Number of 
hospitalizations in 1 
year FU 
LI: 14 
Chronic 
1 (CAN +)  
1 (CAN -) 
[YES] 
145 0·38 
[0.05; 
0.71 
N/A 
van der Meer and 
Velthorst (2015)22 / 
Netherlands 
Use < 5 times/ in 3 year 
FU (n=146) 
No cannabis history 
(n=257) 
Number of relapses 
(hospitalization and/or 
exacerbation of 
psychotic symptomsa) 
in 3 year FU 
LI: 4 
Early stage 
3 (CAN +)  
3 (CAN -) 
[YES] 
403 0·23 
[0.03; 
0.43] 
N/A 
Wade et al. (2006)74 / 
Australia 
 
 
 
 
Presence of CUD during 
FU (n=40) 
Absence of CUD during 
FU (n=48) 
Relapse (y/n) 
(exacerbation of 
psychotic symptomsb) 
LI: 1.3 
Early stage	 1.3 (CAN +)  1.3 (CAN -) 
[YES] 
88 0.87 
[0.41; 
1.33] 
4.87 
[2.09; 
11.32] 
Discontinued Cannabis use   
Study / Country Definition 
discontinued 
cannabis use 
Definition cannabis 
non-user 
Relapse definition Length of Illness 
(LI) in years at FU; 
Illness stage (Early 
vs Chronic) 
FU duration 
(years) 
[Matched 
YES/No] 
N d (p)  
Baeza, Graell (2009)26 / 
Spain 
Use at baseline but no 
use 1 month prior FU 
assessment (n=16) 
No cannabis history 
(n=69) 
Number of 
Rehospitalizations in 
6 months FU 
LI: 1 
Early stage 
0·5 (CAN +)  
0·5 (CAN -) 
[YES] 
85 0         
[-0.57; 
0.57] 
N/A 
González-Pinto, Alberich 
(2009)21 / Spain 
Stopped use between 
onset and 7 years FU 
(n=27) 
No cannabis history 
(n=40) 
Number of 
hospitalizations in 8 
years FU 
LI: 8 
Chronic 
8 (CAN +)  
8 (CAN -) 
[YES] 
67 0·25 [-
0.25; 
0.75]   
N/A 
Maremmani, Lazzeri 
(2004)66 / Italy 
Lifetime CUD but  -ve 
UDS / (n=23) 
 
No cannabis history 
(n=45) 
Number of previous 
hospitalizations 
LI: 9 
Chronic 
9 (CAN +)  
12 (CAN -) 
[NO] 
68 -0·08  
[-0.60; 
0.43] 
N/A 
Martinez-Arevalo, 
Calcedo-Ordo (1994)67 / 
Spain 
No use during 1 year FU 
but previous use (n=25) 
No cannabis history 
(n=24) 
 
Hospitalization (y/n) 
in 1 year FU 
LI: 2 
Early stage 
1 (CAN +)  
1 (CAN -)  
[YES] 
49 0·02    
[-0.56; 
0.60] 
1.03 
[0.36; 
2.95] 
Negrete, Knapp (1986)55 
/ Canada 
History of use but no use 
in 6 months prior FU 
assessment (n=51) 
No cannabis history 
(n=61) 
Number of previous 
hospitalizations 
LI: 11 
Chronic 
9 (CAN +)  
13 (CAN -) 
[NO] 
112 0·22   
[-0.16; 
0.60] 
N/A 
van der Meer and 
Velthorst (2015)22 / 
Netherlands 
Past use < 5 times/ 
lifetime but no use in 3 
year FU (n=266) 
No cannabis history 
(n=257) 
Number of relapses 
(hospitalization 
and/or drop score on 
symptom scale) in 3 
year FU 
LI: 5 
Early stage 
3 (CAN +)  
3 (CAN -) 
[YES] 
523 -0·04  
[-0.21; 
0.13] 
N/A 
CI = Confidence interval; CUD = Cannabis use disorder (DSM or ICD based diagnosis of cannabis abuse or dependence); d = Effect size Cohen’s d with p-value for Random Effects 
Model; FU = Follow up; LI = Length of illness in years at time of follow up assessment; Matched = YES if difference in follow up between CAN(+) and CAN(-) not more than 1 year, 
NO = if difference more than 1 year; NS = Not specified; N/A = Not applicable; OR = Odds Ratio; UDS = Urine drug screen; Stage of illness = Early stage (illness less < 5 years), 
Chronic (illness > 6 years).   
a Based on rating scale: Comprehensive Assessment of Symptoms and History 75 
b Based on rating scale: Brief Psychiatric Rating Scale 76  
c Diagnosed if consumed regularly for several months and if this interfered with social functioning or was prominent during therapy. Patients with occasional use were not included 
 
 
Random Effects Model: Effect of ongoing cannabis use on relapse  
As shown in Figure 2. (cf. sTable 2., supplementary material), continued cannabis use 
post-onset of illness was significantly associated with relapse of psychosis (dCC-
NC=0·36, p<0·0001 [95% CI 0·22; 0·50]). An effect of a similar magnitude was found 
on length of hospitalization after onset (dCC-NC=0·36,  p=0·02[95% CI 0·13; 0·58]). 
For a subset of studies (k=4, n=688) we were able to calculate the number of days 
spent in hospital per year of illness following onset, estimated as the weighted mean 
difference (WMD) (cf. supplementary material, sMethods1. for method description). 
The results indicated that cannabis users spent an additional 8·47 days in hospital per 
year of illness, although this difference was statistically not significant (p=0·20) 
which may reflect the lack of power (cf. sTable 3. supplementary material). Among 
the studies that examined the risk of relapse (k=7, n=2298, cf. Table 1.), the pooled 
odds were 1·97[95% CI 1·46; 2·65] times greater among those who continued to use 
cannabis compared with those who did not (p<0·0001). Limiting analysis to only 
those studies that reported on relapse rates in individuals with the three patterns of 
cannabis use of interest in this context, i.e. continued cannabis user, discontinued user 
and non-user (CC-DC-NC, k=6; N=1172) revealed that this adverse effect of cannabis 
in continued users remained when compared to those who discontinued (dCC-DC=0·28, 
p=0·0005, [95% CI 0·12; 0·44]). In contrast, those who discontinued cannabis use did 
not significantly differ from the non-users in their relapse outcome (dDC-NC=0·02, 
p=0·82[95% CI -0·11; 0·15]) (cf. Figure 3. for a summary). Including all identified 
studies in meta-regression to compare the difference in effect size d between 
continued cannabis users and those who discontinued relative to corresponding non-
user groups (dCC-NC=0·36 vs. dDC-NC=0·02) also confirmed that the effect-sizes were 
significantly different between the two sets of comparisons (p=0·04; cf. sTable 2, 
supplementary material).  Egger’s test and funnels plot (cf. sFigure 2 and sTable 2, 
supplementary material) indicated evidence of funnel plot asymmetry for relapse 
(p=0·0002), but the trim-and-fill method (R0 estimator) did not indicate missing 
studies, suggesting that the asymmetry may be due to other causes such as study 
heterogeneity 77,78. 
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Random Effects Model: Effects of ongoing cannabis use on other outcome measures 
As summarized in Figure 4., continued cannabis use significantly predicted positive 
symptom severity (dCC-NC=0·15, p=0·04[95% CI 0·01; 0·29]). These effects on 
positive symptoms were not present in those who discontinued using the substance 
(dDC-NC=-0·30, p=0·39[95% CI -0·99; 0·38]) and meta-regression indicated that the 
effect-sizes (dCC-NC vs. dDC-NC) were significantly different (p=0·05). Interestingly, 
while continued cannabis users showed comparable levels of functioning when 
compared to the non-users (dCC-NC=0·04, p=0·68[95% CI -0·14; 0·21]), those who 
discontinued using cannabis had significantly higher levels of functioning when 
compared to non-users (dDC-NC=-0·49, p=0·002[95% CI -0·81; -0·17]). This 
difference in effect-size (dCC-NC vs. dDC-NC) was significant as indicated by meta-
regression (p=0·0075). Continued cannabis use was not a significant predictor for 
negative symptomatology (dCC-NC=-0·09, p=0·37[95% CI -0·30; 0·11]) and there was 
a trend for reduced negative symptoms in those who discontinued compared to non-
users (dDC-NC=-0·31, p=0·10[95% CI -0·67; 0·05]). However, the difference in effect 
size (dCC-NC vs. dDC-NC) was not significant (meta-regression, p=0·41). This is also in 
accordance with the direct comparison between continued and discontinued users 
(CC-DC, cf. Table 4.), which suggested that those who continued smoking cannabis 
had higher levels of negative symptoms than those who discontinued. However, this 
was only significant at a trend level (p=0·07) and generalizability may be limited due 
to the few studies included in this analysis (k=2, n=83). 
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Sensitivity Analysis  
There was substantial heterogeneity in the effect of continued cannabis use on relapse 
(83·62%, p<0·0001[95% CI 68·04%; 92·89%]). Hence, sensitivity analysis was 
carried out with more homogeneous groups of studies (for a summary see sTable 4., 
supplementary material): Studies were selected if they matched the follow up duration 
between continued cannabis users and non-users (cf. Table 1., “Matched=YES”) 
(k=17, n=15371, d CC-NC=0·42, p<0·0001[95% CI 0·26; 0·57]), were rated as “high 
quality” (k=10, n=1366, d CC-NC=0·50, p<0·0001[95% CI 0·32; 0·68], included either 
only early stage psychosis (k=10, n=1120, d CC-NC=0·30, p=0·0004[95% CI 0·13; 
0·47])  or chronic psychosis (k=13, n= 14922, d CC-NC=0·37, p=0·0006[95% CI 0·16; 
0·58]) and defined relapse as hospital admission (k=19, n=15412, d CC-NC=0·36, 
p<0·0001[95% CI 0·19; 0·52]). Effect-sizes estimated for studies including only 
patients with non-affective psychosis (k=9, n=1280, d CC-NC=0·34, p=0·0036[95% CI 
0.11; 0.58]) and those including only affective psychosis (k=15, n=14877, d CC-
NC=0·37, p<0·0001[95% CI 0·19; 0·55] were not significantly different (p=0·89). 
Gender and age at follow up assessment did not significantly (p=0·87 and p=0·38) 
reduce the heterogeneity in relapse outcome, as indicated by meta-regression. 
4. Discussion 
To our knowledge, this is the first meta-analysis to demonstrate that, regardless of the 
stage of their psychotic disorder, patients who continue using cannabis are more likely 
to suffer from a relapsing course when compared both to non-using patients (d CC-
NC=0·36) and to patients who discontinue using the substance after onset (d CC-
DC=0·28). Furthermore, considering that those who discontinue do not differ from the 
non-users in their relapse outcome (d DC-NC=0·02), these results suggest that the 
increased relapse rate associated with cannabis use may resolve following 
discontinuation of its use. Gradient in the effect of cannabis use (continued use > 
discontinued use >  non-use) on outcome in psychosis observed in the present 
analysis is consistent with that noted in other studies not included here 15,24, with the 
effect on outcome being most adverse in those who continue to use the drug. This is 
also compatible with other epidemiological evidence of the adverse effects of 
cannabis being dose-dependent 13,65 and with evidence that the magnitude of cognitive 
impairments associated with cannabis exposure tend to diminish following abstinence 
79. Additionally, our results suggest that continued cannabis users suffered 
significantly longer hospitalizations following their onset than non-users (d CC-
NC=0·36), which may suggest perhaps more severe relapses requiring longer inpatient 
care to stabilize. It is worth noting that longer hospital stay may also be related to 
other factors unrelated to the severity of the illness, such as lack of suitable 
accommodation for the patient to be discharged to.  
In terms of symptomatic outcome, continued cannabis users experienced more severe 
positive psychotic symptoms at follow-up assessment.  This effect was not present in 
those who discontinued using the substance (d CC-NC=0·15 vs. d CC-DC=-0·30). This is 
consistent with other follow-up studies that compared positive symptom levels 
between continued users, discontinued users and non-users of cannabis 22-25 and a 
report from a longitudinal population-based sample suggesting that continuation of 
cannabis use predicted subsequent persistence of psychotic symptoms 80. Other 
studies have reported a temporal association between changes in cannabis use and 
subsequent changes in psychotic symptom severity, both in the short 81 and long-term 
14. Evidence that cannabis use has a particularly harmful effect on different outcome 
measures of psychosis (relapse, psychotic symptoms) when use is continued 
compared to when one stops using is intuitive and consistent with effects of cannabis 
use on cognition 79. However, the effect of cannabis and continuity of its use was not 
observed across certain other domains of outcome in the present meta-analysis: 
continued cannabis users did not differ from the non-user groups in their negative 
symptomatology (dCC-NC=-0·09, p=0·37). A similar result was reported in a separate 
meta-analysis focusing on symptoms 32. Discontinued users also did not differ 
significantly from non-users (dDC-NC=-0·31, p=0·10), though they had less negative 
symptoms when compared directly with continued users (dCC-DC=0·41, p=0·07). This 
may appear to contradict the results of the meta-regression suggesting no difference 
between the effects of continued and discontinued use on negative symptoms. 
However, it is worth noting that meta-regression compared the estimates from two 
different random effects models (i.e., dCC-NC and dDC-NC) examining effect on negative 
symptoms, rather than a direct comparison between discontinued and continued 
cannabis users. Furthermore, while the direct comparison involved data from only two 
studies, the meta-regression compared data from a larger sample of studies. 
Nevertheless, it is worth noting that the general direction of effect in different groups 
is consistent across all comparisons. Continued cannabis users showed similar levels 
of functioning when compared to the non-users (dCC-NC=0·04, p=0·68), while 
discontinued users had better functioning scores compared to non-users (dDC-NC=-
0·49, p=0·002). In line with this, other studies have reported that those who 
discontinue cannabis have better functioning 22,24-26 compared to non-users and a 
recent meta-analysis suggested that cessation of substance use in general was 
associated with improvement of negative symptoms and global functioning 34. These 
findings suggest that cannabis-using patients may have better functioning to begin 
with (though this is not something that could be tested in the present analysis). This is 
also compatible with the view that cannabis-using patients represent a subgroup with 
a less neurodevelopmental pathology 82,83; perhaps for this reason the adverse effects 
of cannabis use on functioning and negative symptoms only become apparent when 
continued users are compared to those who discontinued use rather than non-users. 
Patients who are able to stop using cannabis may also represent an etiologically and 
clinically distinct subgroup suffering from a less severe illness with less of a need to 
use cannabis for self-medication. The observed association between cannabis 
exposure and relapse of psychosis and related outcome variables may be mediated 
through the effect of its key psychoactive ingredient, THC, on the neural substrates 
implicated in psychosis 18-20,84-86. The observed strength of association between 
continued cannabis use and relapse is comparable to other identified environmental 
risk factors for relapse of psychosis such as high expressed emotions (d=0·31) 87, as 
well as the effects of interventions that prevent relapse, such as psychoeducation 
(d=0·21)88 or reduce psychotic symptoms, such as antipsychotic treatment (d=0·48) 
89. Hence, these results emphasize the importance of cannabis use as a clinically 
relevant target for treatment development.  
Limitations 
Some limitations are noteworthy, which are mainly related to the methodological 
heterogeneity among the studies included (cf. Table 1). Different criteria were applied 
by the studies included in this meta-analysis to classify those who continued to use 
cannabis (e.g. presence of cannabis use disorder/use more than once in a defined time-
period), or discontinued the drug (e.g. history of use but negative UDS/no use in 
given time period), as well as non-users (e.g. less than daily use/non-abuser/no use in 
given time period/never use). Follow-up durations also differed between cannabis 
users and non-users in some studies [e.g. 7 year relapse window for cannabis users vs. 
12 year relapse window for non-users in Maremmani, Lazzeri (2004)66]. In fact, 
excluding those studies with differing follow-up windows between the participant 
groups as part of sensitivity analysis revealed a slightly larger effect of cannabis use 
on relapse than found in the main analysis (d=0·42 vs. d=0·36). The study by Baeza, 
Graell (2009)26 may need to be highlighted in this context, considering that their 
report of absence of adverse effects of cannabis use on relapse may reflect their six 
months follow up, an interval perhaps too short to detect differences in relapse rates 
between the groups. 
It may be argued that the patients differed in their stage of illness across the included 
studies (e.g. early stage vs. chronic psychosis), but sensitivity analysis revealed that 
this did not significantly influence the results. It was not possible to control for the 
effect of other potential confounding factors that may be associated with cannabis use 
such as medication adherence 1,24,25,67,69, engagement with the services 24 or other 
abuse of other drugs1. However, the present results are also consistent with studies 
that have systematically controlled for age, gender, alcohol and drug use, illness 
characteristics (e.g. duration, diagnosis, severity) and medication adherence when 
measuring the effect of cannabis use on relapse 10-12. Another limitation inherent to 
the meta-analytical design relates to our inability to analyze raw data, which limited 
our ability to carry out moderation analysis to directly test for more defined dose-
response patterns such as frequency, duration or age of onset of use or type of 
cannabis consumed - factors that are also likely to moderate the effect of cannabis on 
relapse 13,65. A further potential source of heterogeneity may be related to the use of 
different types of cannabis containing differing proportion of the main ingredients 
such as delta-9-tetrahydrocannabinol or Cannabidiol that are known to have opposing 
effects90. However, we were unable to assess the effect of type of cannabis used, as 
this information was not available for the included studies. Finally, although our 
systematic search may have been somewhat restricted by using MEDLINE only, we 
aimed to address this potential limitation by screening bibliographies from previous 
conducted meta-analyses, systematic reviews and original studies for additional 
studies that may have been missed out in the database search. 
Nevertheless, despite lack of more fine-grained measures, this meta-analysis detected 
a fairly robust pooled effect of continued cannabis exposure on relapse outcome and 
other measures suggestive of adverse outcome, which were absent in those who 
discontinued use of the drug. The fact that the effects of continued use of cannabis or 
its discontinuation are consistent across different measures of outcome only serves to 
underline the importance of addressing continued cannabis use in patients with 
psychosis in the clinical setting, by highlighting that outcomes are likely to be better 
in those who discontinue the drug.  
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